{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:56:06Z","timestamp":1794009366817,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40257-024-00874-z","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T19:01:33Z","timestamp":1720897293000},"page":"795-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sequencing of Targeted Therapy in Psoriasis: Does it Matter?"],"prefix":"10.1007","volume":"25","author":[{"given":"Nicole D.","family":"Boswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"6","key":"874_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"874_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2023;83(2):199\u2013213. https:\/\/doi.org\/10.1136\/ard-2023-224803.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"874_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/09546634.2015.1086476","volume":"27","author":"M de la Brassinne","year":"2016","unstructured":"de la Brassinne M, Ghislain P, Lambert J, et al. Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: a Belgian perspective. J Dermatol Treat. 2016;27(2):128\u201333. https:\/\/doi.org\/10.3109\/09546634.2015.1086476.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"874_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40257-020-00569-1","volume":"22","author":"CE Heron","year":"2021","unstructured":"Heron CE, Ghamrawi R, Balogh E, et al. Immunogenicity of biologic and biosimilar therapies for psoriasis and impact of novel immunoassays for immunogenicity detection. Am J Clin Dermatol. 2021;22(2):221\u201331. https:\/\/doi.org\/10.1007\/s40257-020-00569-1.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"874_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1346-8138.14834","volume":"46","author":"B Bayaraa","year":"2019","unstructured":"Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46(5):389\u201398. https:\/\/doi.org\/10.1111\/1346-8138.14834.","journal-title":"J Dermatol"},{"issue":"10","key":"874_CR6","first-page":"657","volume":"11","author":"SR Dalal","year":"2015","unstructured":"Dalal SR, Cohen RD. What to do when biologic agents are not working in inflammatory bowel disease patients. Gastroenterol Hepatol (N Y). 2015;11(10):657\u201365.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"874_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00280-022-04418-2","volume":"89","author":"M Borreg\u00f3n","year":"2022","unstructured":"Borreg\u00f3n M, Mart\u00ednez K, Ramos A, et al. Anti-drug antibodies in the current management of cancer. Cancer Chemother Pharmacol. 2022;89(5):577\u201384. https:\/\/doi.org\/10.1007\/s00280-022-04418-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"874_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.23736\/s0392-0488.16.05463-8","volume":"153","author":"G Ganzetti","year":"2018","unstructured":"Ganzetti G, Campanati A, Bettacchi A, et al. Switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group. G Ital Dermatol Venereol. 2018;153(1):5\u201310. https:\/\/doi.org\/10.23736\/s0392-0488.16.05463-8.","journal-title":"G Ital Dermatol Venereol"},{"issue":"3","key":"874_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp K, Griffiths C, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"874_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong A, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"10198","key":"874_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(19)30952-3.","journal-title":"Lancet"},{"key":"874_CR12","unstructured":"Warren R. Efficacy and safety after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab. 2023: AAD 2023 Annual Meeting, 17\u201321 March, New Orleans, USA."},{"issue":"1","key":"874_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139. https:\/\/doi.org\/10.1111\/bjd.19341.","journal-title":"Br J Dermatol"},{"issue":"10148","key":"874_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/s0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(18)31713-6.","journal-title":"Lancet"},{"issue":"12","key":"874_CR15","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jdv.16521","volume":"34","author":"B Strober","year":"2020","unstructured":"Strober B, Menter A, Leonardi C, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830\u20138. https:\/\/doi.org\/10.1111\/jdv.16521.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"874_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2102388.","journal-title":"N Engl J Med"},{"issue":"1","key":"874_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjd.18623","volume":"183","author":"RB Warren","year":"2020","unstructured":"Warren RB, Barker JNWB, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-\u03b1 inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2020;183(1):60\u201370. https:\/\/doi.org\/10.1111\/bjd.18623.","journal-title":"Br J Dermatol"},{"issue":"6","key":"874_CR18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/bjd.20413","volume":"185","author":"AB Gottlieb","year":"2021","unstructured":"Gottlieb AB, Merola JF, Reich K, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124\u201334. https:\/\/doi.org\/10.1111\/bjd.20413.","journal-title":"Br J Dermatol"},{"issue":"12","key":"874_CR19","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1007\/s13555-022-00834-7","volume":"12","author":"B Lockshin","year":"2022","unstructured":"Lockshin B, Harrison RW, McLean RR, et al. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022;12(12):2797\u2013815. https:\/\/doi.org\/10.1007\/s13555-022-00834-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"874_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023;89(3):486\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"874_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311(5):421\u20134. https:\/\/doi.org\/10.1007\/s00403-019-01907-y.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"874_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/2475530319867095","volume":"4","author":"K Papp","year":"2019","unstructured":"Papp K, Blauvelt A, Sullivan J, et al. Ixekizumab\u2014an effective and safe treatment for moderate-to-severe plaque psoriasis in patients previously treated with other IL-17 inhibitors: results From IXORA-P. J Psorias Psoriat Arth. 2019;4(4):180\u20135. https:\/\/doi.org\/10.1177\/2475530319867095.","journal-title":"J Psorias Psoriat Arth"},{"issue":"1","key":"874_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaad.2020.07.085","volume":"84","author":"N Loft","year":"2021","unstructured":"Loft N, Halling A, Egeberg A, et al. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):130\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.085.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"874_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40257-019-00490-2","volume":"21","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441\u20137. https:\/\/doi.org\/10.1007\/s40257-019-00490-2.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"874_CR25","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","volume":"35","author":"SM Reddy","year":"2016","unstructured":"Reddy SM, Crean S, Martin A, et al. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol. 2016;35(12):2955\u201366. https:\/\/doi.org\/10.1007\/s10067-016-3425-4.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"874_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/bjd.19575","volume":"184","author":"R Reddy","year":"2021","unstructured":"Reddy R, Pannu S, Fiumara K, et al. Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment. Br J Dermatol. 2021;184(3):559\u201361. https:\/\/doi.org\/10.1111\/bjd.19575.","journal-title":"Br J Dermatol"},{"issue":"1","key":"874_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"874_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367\u201377. https:\/\/doi.org\/10.3899\/jrheum.170429.","journal-title":"J Rheumatol"},{"issue":"11","key":"874_CR29","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Combe B, Kremer JM, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57(11):2001\u201311. https:\/\/doi.org\/10.1093\/rheumatology\/key182.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"874_CR30","first-page":"566","volume":"37","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Marzo-Ortega H, Vender R, et al. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin Exp Rheumatol. 2019;37(4):566\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"10230","key":"874_CR31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325. https:\/\/doi.org\/10.1016\/s0140-6736(20)30265-8.","journal-title":"Lancet"},{"issue":"10230","key":"874_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/s0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(20)30263-4.","journal-title":"Lancet"},{"issue":"10","key":"874_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D33N39N8XM","volume":"18","author":"P Mudigonda","year":"2012","unstructured":"Mudigonda P, Mudigonda T, Feneran AN, et al. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012;18(10):1.","journal-title":"Dermatol Online J"},{"issue":"3","key":"874_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359\u201369. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220991.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"874_CR35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404\u201314. https:\/\/doi.org\/10.1136\/ard-2023-224431.","journal-title":"Ann Rheum Dis"},{"key":"874_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/ccid.s211938","volume":"12","author":"A Pinter","year":"2019","unstructured":"Pinter A, Bonnekoh B, Hadshiew IM, et al. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019;12:509\u201317. https:\/\/doi.org\/10.2147\/ccid.s211938.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"874_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/24755303211037308","volume":"6","author":"EJ Song","year":"2021","unstructured":"Song EJ, Wong A. Tildrakizumab inadequate responders switching to an alternative IL-23 inhibitor: a case series. J Psorias Psoriat Arth. 2021;6(4):166\u20139. https:\/\/doi.org\/10.1177\/24755303211037308.","journal-title":"J Psorias Psoriat Arth"},{"issue":"2","key":"874_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100261","volume":"4","author":"SG Daniele","year":"2024","unstructured":"Daniele SG, Eldirany SA, Damiani G, et al. Structural basis for p19 targeting by anti-IL-23 biologics: correlations with short- and long-term efficacy in psoriasis. JID Innov. 2024;4(2): 100261. https:\/\/doi.org\/10.1016\/j.xjidi.2024.100261.","journal-title":"JID Innov"},{"issue":"3 Suppl 2","key":"874_CR39","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.jaad.2005.10.052","volume":"54","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Ruderman E. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006;54(3 Suppl 2):S85-91. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.052.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"874_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00874-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T11:36:31Z","timestamp":1724844991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00874-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00874-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"6 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has no funding source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kenneth B. Gordon has received honoraria for consulting and\/or received research support from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, UCB, Acelyrin, Almirall, Amgen, Dermavant Sciences, Leo, Novartis, Pfizer, Incyte, Moon Lake, and Protagonist. Shikha Singla has received honoraria for consulting from AbbVie, UCB, and Janssen and a research grant from Prometheus Biosciences. Nicole D. Boswell has no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval (appropriate approvals or waivers)"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"Kenneth B. Gordon formulated the concept for this article. All authors contributed to the study design. Nicole D. Boswell performed the literature search, data analysis, and drafted the manuscript with creation of the figures and tables. Kenneth B. Gordon and Shikha Singla critically revised the manuscript. All authors approved the final draft for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}